• Operating revenue up 103% YTD with 91.4% gross margins
• Key contract wins including 3-year renewal with Cleveland Clinic
• Cost reduction program delivering $6.5m in annualized savings

4DMedical Limited (ASX:4DX) has announced its Quarterly Activity Report and Appendix 4C Cash Flow Report for Q3 FY2025. Operating revenue for YTD FY2025 was $4.5m, up 103% vs prior corresponding period, with gross margins of 91.4%. The company continued to grow its global site and scan numbers, now delivering SaaS products at 361 sites globally. 4DMedical announced a cost reduction program delivering $6.5m in annualized savings, driven by headcount reductions. The company's CT:VQâ„¢ product is nearing FDA submission, with growing interest from academic medical centers and industry partners. 4DMedical also announced several key contract wins, including a 3-year SaaS renewal with the Cleveland Clinic and new commercial contracts with Qscan Radiology Clinics and Integral Diagnostics in Australia. The company highlighted its growing partnership with Philips, with over 200 Philips sales personnel trained to sell 4DMedical products. 4DMedical also received regulatory approval for its CT LVASâ„¢ product in Canada, expanding its global footprint.

4DMedical expects to continue its strong organic growth through the rest of calendar 2025, with the company's partnership with Philips driving additional momentum.

The company is entering an exciting quarter ahead, with key milestones expected to be achieved, including the FDA submission for its CT:VQâ„¢ product. 4DMedical sees a significant opportunity to realign its share price to its operational success in the year ahead.